drug pricing

First Opinion By Dan Ollendorf

Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it

Pharmalot By Ed Silverman

Incyte pays $12.6 million to resolve claims it paid drug kickbacks through charity

Politics By Nicholas Florko

Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms 

Pharmalot By Ed Silverman

Rising wholesale drug prices really do matter to half of all commercially insured Americans

Pharmalot By Megan Thielking

STAT+ Conversations: An update from STAT’s Pharmalot

Pharmalot By Ed Silverman

Pharmalittle: Wyden goes back to the drawing board on drug pricing; Emergent undergoes an executive shake-up

Pharmalot By Ed Silverman

Will India issue sidestep patents on a pair of pricey — but lifesaving — TB drugs?

Pharmalot By Ed Silverman

Thanks to its Covid-19 response, pharma’s reputation among patient groups is climbing

Pharmalot By Ed Silverman

Down and out Down Under? Bristol Myers fights an ‘unreasonable’ Australian law over patents

Pharmalot By Ed Silverman

The price of a Vertex cystic fibrosis treatment stirs anger in Australia

Pharmalot By Ed Silverman

‘There are no alternatives’: As Pfizer discontinues an old glaucoma drug, a small group of patients struggles to cope

Politics By Nicholas Florko and Rachel Cohrs

Worried drug pricing reform might be left behind, Democrat pushes Biden to make clear his support

Politics By Nicholas Florko

Hints emerge about a key Senate committee’s plans for health care

Pharmalot By Ed Silverman

A U.S. appeals court upholds the FTC view of controversial pay-to-delay settlements

Politics By Nicholas Florko

PhRMA chief talks strategy — and he’s surprisingly optimistic about drug pricing reform

Pharma By Jessica Davis Plüss

Europe tries to lower drug prices with small doses of transparency

Pharmalot By Ed Silverman

Federal agency says pharma should pay higher Medicaid rebates if certain trials aren’t finished on time

Pharmalot By Ed Silverman

Brazilian judge temporarily suspends pharmaceutical patent extensions amid push to lower drug costs

Pharmalot By Ed Silverman

A controversial court case in Brazil will tackle pharma ‘monopolies’ and access to drugs

Pharmalot By Ed Silverman

California once again delays launch of a closely watched prescription drug purchasing program

Pharmalot By Ed Silverman

Lilly is a holdout among companies that agree to disclose when executive pay is clawed back

Pharmalot By Ed Silverman

Bristol Myers Squibb agrees to pay $75 million to settle allegations of underpaying Medicaid rebates

Pharmalot By Ed Silverman

Most U.S. universities get an ‘F’ on ensuring access to drugs they discover

Politics By Rachel Cohrs

Here are the drug pricing policy options Democrats could use to pay for their next big legislative push

Pharmalot By Ed Silverman

Congressional lawmakers urge FTC to investigate insulin makers over their pricing